C/EBPs, particularly C/EBPb and C/EBPd, are known to participate in the regulation of many genes associated with inflammation. However, very little is known regarding the activation and functions of C/EBPb and C/EBPd in acute lung inflammation and injury. In this study, we show that both C/EBPb and C/EBPd activation are triggered in lungs and in alveolar macrophages following intrapulmonary deposition of IgG immune complexes. We further show that mice carrying a targeted deletion of the C/ EBPb gene displayed significant attenuation of the permeability index (lung vascular leak of albumin), lung neutrophil accumulation (myeloperoxidase activity), total number of WBCs, and neutrophils in bronchoalveolar lavage fluids compared with wildtype mice. Moreover, the mutant mice expressed considerably less TNF-a, IL-6, and CXC/CC chemokine and soluble ICAM-1 proteins in bronchoalveolar lavage fluids, and corresponding mRNAs in the IgG immune complex-injured lung, compared with wild-type mice. These phenotypes were associated with a significant reduction in morphological lung injury. In contrast, C/EBPd deficiency had no effect on IgG immune complex-induced lung injury. IgG immune complex-stimulated C/EBPb-deficient alveolar macrophages released significantly less TNF-a, IL-6, MIP-2, keratinocyte cell-derived chemokine, and MIP-1a compared with wild-type cells. Similar decreases in IgG immune complex-induced inflammatory mediator production were observed following small interfering RNA ablation of C/EBPb in a murine alveolar macrophage cell line. These findings implicate C/EBPb as a critical regulator of IgG immune complex-induced inflammatory responses and injury in the lung. The Journal of Immunology, 2012, 189: 000-000. C /EBPs a, b, d, ε, g, and z comprise a family of basic region-leucine zipper transcription factors that dimerize through a leucine zipper and bind to DNA through an adjacent basic region (1). Among them, C/EBPb and C/EBPd appear to be effectors in the induction of genes responsive to LPS, IL-1, or IL-6 stimulation, and have been implicated in the regulation of inflammatory mediators as well as other gene products associated with the activation of macrophages and the acute-phase inflammatory response (2-8). Both C/EBPb and C/EBPd are expressed in the lung, and agents including classical acute-phase stimuli as well as those causing acute lung injury such as bleomycin and oxidative stress have been shown to increase the levels of C/EBPb and C/EBPd in the lung (9, 10). However, the signals that mediate the activation of C/EBPb and C/EBPd and their function in lung during inflammation remain largely unknown. A recent study demonstrates that C/EBPb in the airway epithelium mediates inflammatory and innate immune responses in lung to cigarette smoke (11). C/EBPb was also reported to play an essential role in bleomycin-induced pulmonary fibrosis (12). These observations suggest that C/EBPb and/or C/EBPd may play important roles during lung inflammation. However, no information exists about the role of C/EBPb and C/EBPd in acute lung injury.
C /EBPs a, b, d, ε, g, and z comprise a family of basic region-leucine zipper transcription factors that dimerize through a leucine zipper and bind to DNA through an adjacent basic region (1) . Among them, C/EBPb and C/EBPd appear to be effectors in the induction of genes responsive to LPS, IL-1, or IL-6 stimulation, and have been implicated in the regulation of inflammatory mediators as well as other gene products associated with the activation of macrophages and the acute-phase inflammatory response (2) (3) (4) (5) (6) (7) (8) . Both C/EBPb and C/EBPd are expressed in the lung, and agents including classical acute-phase stimuli as well as those causing acute lung injury such as bleomycin and oxidative stress have been shown to increase the levels of C/EBPb and C/EBPd in the lung (9, 10) . However, the signals that mediate the activation of C/EBPb and C/EBPd and their function in lung during inflammation remain largely unknown. A recent study demonstrates that C/EBPb in the airway epithelium mediates inflammatory and innate immune responses in lung to cigarette smoke (11) . C/EBPb was also reported to play an essential role in bleomycin-induced pulmonary fibrosis (12) . These observations suggest that C/EBPb and/or C/EBPd may play important roles during lung inflammation. However, no information exists about the role of C/EBPb and C/EBPd in acute lung injury.
The IgG immune complex model in the rodent lung have been employed to determine the molecular mechanisms of acute lung inflammatory injury (13, 14) . In this model, intra-alveolar deposition of IgG immune complexes results in an acutely damaging process that affects capillary endothelial cells and alveolar epithelial cells, and also stimulates alveolar macrophages. Activation of alveolar macrophages results in formation of the early response cytokines such as TNF-a and IL-6, which induce expression of adhesion molecules on leukocytes and on endothelial cells/epithelial cells, all of which trigger a strong proinflammatory cascade. The induction of cytokine and chemokine gene expression involves the actions of specific transcription factors. For example, the activation of NF-kB and AP-1 has been observed in IgG immune complex-injured lung (15, 16) . However, their functions in IgG immune complex-induced lung injury are only speculative, and no definitive study demonstrates their pivotal roles in the development of lung inflammatory responses. Our recent study indicates that Stat3 may play an important role in IgG immune complex-induced lung inflammation (17) , but the molecular mechanisms responsible for this observation remain to be defined. In this regard, C/EBPb and C/ EBPd have been demonstrated to be targets of Stat3 (18, 19) . In this study, we demonstrate that both C/EBPb and C/EBPd are activated in IgG immune complex-stimulated alveolar macrophages and in lung during IgG immune complex-induced acute lung injury. Importantly, we provide direct evidence that C/ EBPb, but not C/EBPd, is a critical transcription factor that regulates IgG immune complex-induced inflammatory responses in the lung and alveolar macrophages.
Materials and Methods

Cells and reagents
Mouse alveolar macrophage-derived cell line, MH-S, was purchased from American Type Culture Collection (Manassas, VA), and cultured in RPMI 1640 medium supplemented with 10% FBS, 2 mM L-glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin, and 0.01 M HEPES, and maintained in a humidified incubator at 37˚C with 5% CO 2 . BSA was purchased from Sigma-Aldrich (St. Louis, MO). Anti-BSA IgG was purchased from MP Biomedicals (Solon, OH). ELISA kits for mouse IL-6, TNF-a, MIP-2, keratinocyte cell-derived chemokine (KC), MIP-1a, MIP-1b, and soluble ICAM-1 (sICAM-1) were obtained from R&D Systems (Minneapolis, MN).
IgG immune complex-induced acute lung injury
All procedures involving mice were approved by the Animal Care and Use Committee of Harvard Medical School. Eight-to 12-wk-old specific pathogen-free male C57BL/6 mice were obtained from The Jackson Laboratory (Bar Harbor, ME). Generation of Cebpb 2/2 and Cebpd 2/2 mice by homologous recombination has been described previously (20, 21) . Cebpb 2/2 mice and wild-type littermates were on a C57BL/6:Sv129 F 1 hybrid background (to circumvent low mutant viability on each pure strain background), and Cebpd 2/2 animals and wild-type controls were on a C57BL/6 background. Mice were anesthetized i.p. with ketamine HCl (100 mg/kg), followed by intratracheal instillation of 40 ml rabbit anti-BSA IgG dissolved in PBS (6 mg/ml) during inspiration. Immediately after intratracheal injection of anti-BSA, mice received i.v. 200 ml BSA solution (5 mg/ml in PBS). Negative control mice received anti-BSA IgG or PBS intratracheally alone. Unless otherwise indicated, 4 h after IgG immune complex deposition, mice were exsanguinated and the pulmonary circulation was flushed with 1 ml PBS via the pulmonary artery. The lungs were surgically dissected and immediately frozen in liquid nitrogen.
Myeloperoxidase activity
Mice were scarified, and the lungs were perfused via the right ventricle with 3 ml PBS. To measure myeloperoxidase (MPO) activity, whole lungs were homogenized in 50 mmol/l potassium phosphate buffer containing 0.5% hexadecyltrimethylammonium bromide and 5 mmol/L EDTA. The samples were sonicated for 1 min and centrifuged at 10,000 rpm for 10 min. A total of 10 ml recovered supernatants was added to 96-well plates, followed by addition of 100 mmol/l potassium phosphate buffer containing 1.5 mol/l H 2 O 2 and 167 mg/ml o-dianisidine dihydrochloride. The enzyme activity was determined by measuring the change in OD at 450 nm over a period of 4.5 min using a 96-well plate reader.
Histological assay
Four hours after IgG immune complex deposition, 1 ml 10% buffered (pH 7.2) formalin was instilled into the lung via the trachea. The lungs were then surgically removed and further fixed in 10% buffered formalin solution for morphological assay by tissue sectioning and staining with H&E.
Bronchoalveolar lavage fluid collection, total and differential WBC counts, albumin, and chemokine/cytokine ELISAs Four hours after initiation of the acute lung injury, the thorax was opened and 0.8 ml ice-cold, sterile PBS was instilled into the lung via a tracheal incision. The recovered lavage fluid (bronchoalveolar lavage [BAL] ) was centrifuged at 450 3 g for 6 min, and the cell-free supernatants were stored at 220˚C. Cell pellets were resuspended in 1 ml HBSS containing 0.5% BSA, and differential cell analyses were performed by Diff-Quik-stained cytospin preparations (Dade, Duedingen, Switzerland) counting a total of 300 cells per slide in randomly selected high-powered fields (31000). The supernatant was used for cytokine, chemokine, and sICAM-1 measurements by sandwich ELISA. Mouse albumin levels in BAL fluid were measured using a mouse albumin ELISA kit purchased from Bethyl Laboratories (Montgomery, TX). The permeability index was expressed as the ratio of the albumin in the IgG immune complex-injured lungs versus that in the control-treated lungs of same type of mice.
Alveolar macrophage isolation and in vitro IgG immune complex treatment
BAL fluids were collected using repetitive (three times) instillation and withdrawal of 1 ml saline via an intratracheal cannula. BAL samples were centrifuged at 1500 rpm for 10 min, and cell pellets were resuspended and plated in 96-well plate. Alveolar macrophages were allowed to adhere at 37˚C for 1 h, and nonadhering cells were removed. The purity of the cell suspension was ∼96%, which is determined by staining of BAL cells with HEMA 3 STAIN SET, obtained from Fisher Scientific. For IgG immune complex formation in vitro, 100 mg BSA in 100 ml PBS buffer was incubated with 25 ml 2.5 mg/ml anti-BSA IgG at 37˚C for 30 min. Supernatant fluids were collected for assessment of cytokines/chemokines by ELISA.
Assessment of C/EBP activation by EMSA
Nuclear extracts of alveolar macrophages or MH-S were prepared as follows. Cells were washed in PBS and lysed in buffer A (15 mM KCl, 10 mM HEPES [pH 7.6], 2 mM MgCl 2 , 0.1 mM EDTA, 1 mM DTT, 0.1% [v/v] Nonidet P-40, 0.5 mM PMSF, 2.5 mg/ml leupeptin, 5 mg/ml antipain, and 5 mg/ml aprotinin). Proteins were extracted from nuclei by incubation at 4˚C
with vigorous vortexing in buffer C (420 mM NaCl, 20 mM HEPES [pH 7.9], 0.2 mM EDTA, 25% [v/v] glycerol, 1 mM DTT, 0.5 mM PMSF, 2.5 mg/ml leupeptin, 5 mg/ml antipain, and 5 mg/ml aprotinin). Nuclear extracts of whole-lung tissues were prepared, as described previously (17) . C/EBP probes (59-TGCAGATTGCGCAATCTGCA-39; Santa Cruz Biotechnology, Santa Cruz, CA) were labeled with [ 32 P]ATP (3000 Ci/mmol at 10 mCi/ml; Amersham Biosciences, Sunnyvale, CA). EMSA was performed, as described previously (17) . The following Abs were from Santa Cruz Biotechnology: C/EBPa, C/EBPb, C/EBPd, C/EBPε, C/EBPg, and normal rabbit IgG.
Small interfering RNA transfection
Transient small interfering RNA (siRNA) transfections were performed by transfecting 1-2 3 10 6 MH-S cells with control siRNA or C/EBPb siRNA (Santa Cruz Biotechnology) using Amaxa nucleofector kit V. Twelve hours later, MH-S cells were treated with or without 100 mg/ml IgG immune complexes for 6 h. RNAs were harvested for RT-PCR to analyze downregulation of C/EBPb expression, or supernatants were collected for ELISAs.
Alveolar macrophage depletion
Mice were anesthetized with ketamine HCl (100 mg/kg, i.p.). A suspension of dichloromethylene diphosphonate (Cl 2 MDP) liposomes in PBS (10 ml of the liposome stock in a total volume of 50 ml) was administered intratracheally during inspiration. As a control, PBS liposomes were administered in a similar fashion. All subsequent interventions were performed 24 h after liposome instillation. Liposome-encapsulated clodronate was prepared, as previously described (22) . Mice receiving Cl 2 MDP liposomes showed .75% depletion of alveolar macrophages compared with mice receiving PBS liposomes. Administration of PBS liposomes did not reduce the number of alveolar macrophages.
Luciferase assay
MH-S cells were transfected with indicated reporter plasmids by using Fugene6 Transfection Reagent (Roche, Indianapolis, IN). Forty-eight hours after transfection, cells were treated with or without 100 mg/ml IgG immune complex. Four hours later, cells were lysed in Passive Lysis 53 Buffer (Promega, Madison, WI), and luciferase activity was measured. The mouse IL-6 promoter-reporter and TNF-a promoter-reporter as well as the C/ EBPb expression plasmid and C/EBPd expression plasmid have been described in our previous publications (5, 23, 24) .
RNA isolation and detection of mRNA by quantitative real-time PCR
Total RNAs were extracted from lungs with TRIzol (Invitrogen, Carlsbad, CA), according to the manufacturer's procedure. After isolation, total cellular RNA was incubated with RQ1 RNase-free DNase (Promega) to remove contaminating DNA. A quantity amounting to 2 mg total RNA was submitted to reverse transcription by using the Superscript II RNase H-Reverse Transcriptase (Invitrogen, Carlsbad, CA). Following reverse transcription, the cDNA (2 ml) was amplified and quantified using a Sequence Detection System (SDS 7300; Applied Biosystems, Foster City, CA) and a PCR universal protocol as follows: AmpliTaq Gold activation at 95˚C for 15 s and annealing/extension at 60˚C for 1 min. The fluorescence of the double-stranded products accumulated was monitored in real time. The levels of mRNA of TNF-a, IL-6, MIP-2, and MIP-1a were determined by quantitative real-time PCR. 
Statistical analysis
All values were expressed as the mean 6 SEM. Data sets were analyzed using Student t test or one-way ANOVA, with individual group means being compared with the Student-Newman-Keuls multiple comparison test.
Results
Lung C/EBPs are activated during IgG immune complex-induced alveolitis
We evaluated C/EBP DNA-binding activity in IgG immune complex-injured lung by EMSA (Fig. 1A) . C/EBP-binding species were detected in control-treated lung. Increased C/EBP binding was evident by 1 h after IgG immune complex deposition, and became strongest at 4 and 8 h. Subsequently, C/EBP-binding activity subsided, reaching basal levels by 24 h. To determine which C/EBP family members are induced by IgG immune complexes, we performed supershift assays. As shown in Fig. 1B , there are three major DNA-binding species in the nuclear proteins of control-treated lungs, as follows: low levels of C/EBPa/b heterodimers; heterodimers between C/EBPb (liver-enriched activating protein) and its short isoform, liver-enriched inhibitory protein (LIP), which is translated from an alternative start site in the same mRNA (25) ; and LIP/LIP homodimers. In IgG immune complexinjured lungs, the DNA-binding activities of both C/EBPb (mainly b/LIP and LIP/LIP) and C/EBPd were significantly induced (Fig.  1B) . Using real-time RT-PCR analysis, we further show there is a time-dependent increase in the abundance of lung C/EBPb and C/EBPd transcripts after IgG immune complex deposition (Fig.  1C and data not shown) . Thus, the increased mRNA expression of C/EBPb and C/EBPd is consistent with their increased DNAbinding activity in the lung.
Alveolar macrophages play a key role in the IgG immune complex-induced lung injury (16, 26, 27) . Therefore, we determined whether alveolar macrophage depletion would affect C/ EBP activation in whole-lung tissues 4 h after onset of injury. Mice pretreated with PBS liposomes and challenged with IgG immune complexes showed the expected C/EBP activation (Fig.  1D, lanes 1 and 2) . By contrast, depletion of alveolar macrophages with Cl 2 MDP liposomes markedly reduced the extent of lung C/ EBP activation (Fig. 1D) . These data suggest that alveolar macrophages play a critical role in IgG immune complex-induced activation of C/EBPs in lung.
Effects of C/EBPb deficiency on IgG immune complex-induced lung injury
We sought to determine whether C/EBPb contributed to IgG immune complex-induced lung injury by using C/EBPb-deficient mice. As shown in Fig. 2A , C/EBPb deficiency resulted in a significant decrease (p , 0.001) of permeability index (albumin leakage) when compared with wild-type mice after IgG immune complex deposition. We also examined MPO content to evaluate neutrophil accumulation in lungs (Fig. 2B) . As with albumin leakage, MPO content in C/EBPb-deficient mice was much lower (p , 0.01) when compared with values in control-treated wildtype mice during lung injury. We further found that C/EBPb-deficient mice displayed significant attenuation of the total number of WBCs (by 59%, p , 0.001; Fig. 2C ) and neutrophils (by 61%, p , 0.001; Fig. 2D ) in BAL fluids from IgG immune complex-injured lung compared with wild-type mice. We examined whether C/EBPb-deficient mice exhibited reduced lung injury by histological analyses. As shown in Fig. 2E , both wild-type and C/ EBPb-deficient mice receiving aBSA alone exhibited normal lung architecture. As expected, lung hemorrhage and inflammatory cell influx were observed in wild-type mice after IgG immune complex deposition. In contrast, IgG immune complex-injured lungs from C/EBPb-deficient mice showed significantly decreased neutrophil accumulation and reduced intra-alveolar hemorrhage compared with wild-type animals.
Production of cytokines and chemokines in lung after IgG immune complex deposition is impaired in C/EBPb-deficient mice
We determined BAL levels of several inflammatory cytokines and chemokines that are involved in IgG immune complex-induced lung injury (26) . As expected, wild-type mice undergoing IgG immune complex deposition showed increased production of TNF-a, IL-6, MIP-2, KC, MIP-1a, and MIP-1b compared with controls ( Fig. 3A-F) . The levels of all these inflammatory mediators were dramatically decreased in IgG immune complex-injured mutant mice when compared with wild-type mice. Moreover, in the presence of IgG immune complexes, lung from C/EBPb-deficient mice expressed considerably lower amounts of mRNAs for TNF-a, IL-6, MIP-2, KC, MIP-1a, and MIP-1b (Fig.  3G-L) , compared with the lung from wild-type mice. Adhesion molecules are also involved in lung inflammatory injury after intra-alveolar deposition of IgG immune complexes (28) . Notably, IgG immune complex-injured lungs from C/EBPb-deficient mice showed a marked reduction in ICAM-1 mRNA, whereas very little decrease in VCAM-1 expression was observed (Fig. 4) . Because soluble ICAM-1 can directly bind and activate lung macrophages, and enhance lung injury after intrapulmonary disposition of IgG immune complexes (29), we measured soluble ICAM-1 level in BAL fluids of IgG immune complex-injured lungs. We found that C/EBPb deficiency resulted in a significant decrease (p , 0.01) of ICAM-1 change when compared with wild-type mice after IgG immune complex deposition in the lung (Fig. 5) .
Effects of C/EBPb deficiency on cytokine and chemokine protein production in alveolar macrophages stimulated by IgG immune complexes
We evaluated the effects of C/EBPb deficiency on the expression of cytokines and chemokines in primary alveolar macrophages. Upon IgG immune complex treatment, C/EBPb-deficient alveolar macrophages released significantly less TNF-a, IL-6, MIP-2, KC, and MIP-1a than wild-type macrophages at all time points analyzed ( Fig. 6A-E) . Interestingly, no significant change was found for MIP-1b, suggesting that other cells in the lung may contribute to the reduced levels of this chemokine in the BAL fluid and lung of C/EBPb-deficient mice (Fig. 6F) . We next sought to determine the effects of C/EBPb on inflammatory mediator production following IgG immune complex stimulation of the alveolar macrophage cell line, MH-S. We first show that C/EBP-binding activity (mainly C/EBPb) in IgG immune complex-treated MH-S cells increased with kinetics similar to that of the IgG immune complex-injured lung (Fig. 7A, 7B) . We ablated C/EBPb expression by siRNA-mediated silencing (Fig. 7C) . Analysis of in- flammatory mediator production showed impaired induction by IgG immune complexes following C/EBPb knockdown in MH-S cells (TNF-a decreased by 62%, IL-6 by 77% IL-6, and MIP-2 by 48%, respectively; Fig. 7D-F) .
Effects of C/EBPb overexpression on IgG immune complex-induced TNF-a and IL-6 expression in macrophages
We examined IgG immune complex-induced C/EBP transcriptional activity in transiently transfected MH-S cells using 2XC/ EBP-Luc, a promoter-reporter that contains two copies of a C/ EBP binding site, and an expression vector for C/EBPb (liverenriched activating protein). Consistent with the results from EMSA (Fig. 1) , IgG immune complex stimulation alone induced a 3.8-fold increase in luciferase activity compared with the untreated control (Fig. 8A) . C/EBPb vector alone also elevated 2XC/ EBP-Luc transcription (7.7-fold). Importantly, IgG immune complex treatment of C/EBPb transfectants induced luciferase expression 24-fold over the control value. Because these effects are superadditive, IgG immune complexes may stimulate the intrinsic activity of C/EBPb as well as its expression.
We next evaluated the role of C/EBPb in IgG immune complexinduced transcription from the TNF-a and IL-6 promoters. As shown in Fig. 8B and 8C, IgG immune complex stimulation alone significantly increased luciferase activity (2.2-fold for TNF-a and 4.56-fold for IL-6). C/EBPb overexpression in the absence of IgG immune complex resulted in 4-fold (TNF-a) and 1.56-fold (IL-6) induction of luciferase expression. Importantly, IgG immune complex treatment of C/EBPb transfectants induced luciferase expression 8.6-fold and 9.65-fold for TNF-a and IL-6, respectively. These data are consistent with the ELISA results obtained from primary macrophages and MH-S cells.
Effects of C/EBPd deficiency on IgG immune complex-induced lung inflammatory responses
Because C/EBPd DNA-binding activity was induced by IgG immune complex deposition in the lung (Fig. 1B) , we examined whether C/EBPd contributes to IgG immune complex-induced lung inflammatory responses. As shown in Fig. 9A , there was no significant difference in lung MPO activity between wild-type and C/EBPd-deficient mice 4 h after IgG immune complex deposition. Consistently, BAL fluids from lungs of C/EBPd-deficient mice showed similar levels of TNF-a and MIP-2 when compared with BAL fluids from injured wild-type mice (Fig. 9B, 9C) . We next determined the effects of C/EBPd on the inflammatory mediator production from IgG immune complex-stimulated primary alveolar macrophages. As shown in Fig. 9D -G, C/EBPd deficiency in alveolar macrophages caused only modest decreases in TNF-a, MIP-2, KC, and MIP-1a production compared with wildtype macrophages at all time points analyzed. Thus, C/EBPb (but not C/EBPd) is critical for IgG immune complex-induced inflammatory injury in the lung.
Discussion
The intrapulmonary deposition of IgG immune complexes in mice results in a complex cascade of inflammatory mediators that control an ordered sequence of events, including the activation of residential macrophages and recruitment of neutrophils to the site of injury (26) . Previous studies in this lung model suggest that activation of NF-kB appears to play a central role in the pulmonary inflammatory response to IgG immune complexes (30) . However, no direct evidence supports this hypothesis. Moreover, growing evidence indicates that the regulation of gene expression in the lung is mediated by a highly intricate network of transcription factors (31, 32) . Our recent studies show that Stat3 is activated in both alveolar macrophages and whole-lung extracts following IgG immune complex deposition (17, 33) . Using an adenoviral vector expressing a dominant-negative Stat3 isoform, we further show that Stat3 plays an important regulatory role in the pathogenesis of IgG immune complex-induced acute lung injury (17) . Because the promoter regions of several important inflammatory mediators such as IL-6 and TNF-a do not contain functional Stat3 binding sites, the molecular mechanism whereby Stat3 regulates lung inflammation remains unknown. Interestingly, it has been demonstrated that Stat3 can bind the promoter regions of both C/EBPb and C/EBPd, which are involved in IL-6 signaling in hepatoma cells (19) . Thus, we hypothesized that Stat3 may regulate lung inflammation by affecting C/EBP activity. In the current study, we have identified C/EBPb as a critical mediator of IgG immune complex-induced acute lung injury and inflammatory response in alveolar macrophages. C/EBPb and C/EBPd are expressed in many tissues, including lung. However, the expression and function of C/EBPb and C/ EBPd during acute lung inflammatory response are still largely unknown. We now provide evidence that both C/EBPb and C/ EBPd are activated in lung during IgG immune complex-induced acute lung injury. We further show the IgG immune complexes regulate the lung expression of C/EBPb and C/EBPd at mRNA level ( Fig. 1C and data not shown) . However, the molecular mechanisms by which IgG immune complexes induce C/EBPb and C/EBPd gene expression in the lung remain unclear. We recently found that C/EBP activation in peritoneal macrophages is mediated, to a large extent, by Fcg receptors (FcgRI and FcgRIII) (34) . Therefore, it would be interesting to investigate in the future study whether FcgR signaling is involved in the C/EBP activation after IgG immune complex deposition in the lung. C/EBPb is a known regulator of several genes that are involved in the inflammatory responses, including those coding for cytokines, chemokines, and their receptors and acute-phase proteins (2) . In the current study, we have used C/EBPb-deficient mice to clearly demonstrate that C/EBPb play a critical role in acute lung inflammation and injury. The current data indicate that several mechanisms are involved in C/EBPb regulation of acute immunological pulmonary alveolitis. Our results that C/EBPb deficiency significantly mitigates IgG immune complex-induced lung injury as defined by decreased albumin leakage into lung and reduced MPO content as well as less BAL cells indicate a critical role for C/EBPb in neutrophil accumulation in lung. Neutrophil transmigration into the alveolar compartment and lung interstitium plays a key role in the development of acute lung injury. Using an Ab-mediated blocking approach, both the CXC chemokines (MIP-2 and KC) and CC chemokines (MIP-1a and MIP1b) have been shown to play an important role in intrapulmonary recruitment of neutrophils and development of lung injury induced by the IgG immune complex deposition (35) (36) (37) . Our observation that C/EBPb deficiency resulted in a significant decrease of these chemokines in BAL fluids from IgG immune complex-injured lungs supports this hypothesis. Another possible mechanism is the C/EBPb regulation of TNF-a and IL-6, both of which play an important role in the development of acute lung injury by inducing the expression of molecules mediating adhesive interactions between endothelial cells and leukocytes (38) . Indeed, we show that C/EBPb deficiency caused a reduced expression of TNF-a and IL-6 as well as ICAM-1 in the lung. Together, our data suggest that upon IgG immune complex deposition, C/EBPb affects neutrophil migration into lung and alveolar space by regulating the expression of chemokines, cytokines, and adhesion molecule.
Alveolar macrophages function as regulatory cells that secrete TNF-a and other cytokines and chemokines to modulate the cell signaling cascade for the production of other inflammatory mediators during lung inflammation (2, 50). We previously showed that depletion of alveolar macrophages resulted in significantly reduced expression of inflammatory cytokines and chemokine genes in IgG immune complex-injured rat lungs (33) . Data in the current study show that C/EBP activation induced by IgG immune complexes is suppressed by depletion of alveolar macrophages in whole lung tissues (Fig. 1D) . Moreover, employing mice deficient for C/EBPb, siRNA-mediated knockdown in cell lines, and luciferase reporter assays, we show that C/EBPb plays a critical role in the production of cytokines and chemokines in IgG immune complex-stimulated macrophages. These data together indicate that C/EBPb activation in alveolar macrophages is a key event in IgG immune complexinduced lung injury.
All C/EBP members can form homo-and heterodimers with other family members. It has been noted that, depending on the composition, C/EBP complexes may be associated with function differences in cell growth, cell activation, and apoptosis (39) . However, several studies have suggested compensatory or redundant roles for C/EBPs, including C/EBPb and C/EBPd, in supporting the induction of inflammatory cytokines and chemokines. For example, LPS stimulation of peritoneal macrophages from C/EBPb-deficient mice led to normal induction of several inflammatory cytokines, including IL-6 and TNF-a, with the exception of G-CSF, Mincle, and mPGES-1 (4, (40) (41) (42) . Using a B lymphoblast system, Hu et al. (5) reported that the activities of C/EBPa, C/EBPb, and C/EBPd are redundant in regard to the expression of IL-6 and MCP-1. In addition, a recent study shows that C/EBPd-deficient macrophages have no significant defects in IL-6 and TNF-a production in response to several TLR ligands, whereas the absence of both C/EBPb and C/EBPd results in a significant decrease in the TLR ligandinduced production of IL-6 and TNF-a (43) . Interestingly, our recent study shows that lack of either C/EBPb or C/EBPd has a significant effect on the production of TNF-a, MIP-2, and MIP-1a in IgG immune complex-stimulated peritoneal macrophages, indicating the possible importance of C/EBPb and C/ EBPd heterodimer occupancy in regulating these promoters (34) . In this report, we have directly compared the effect of C/EBPb and C/EBPd deficiency on lung inflammatory responses. We clearly show that C/EBPd could not compensate for C/EBPb deficiency in the IgG immune complex lung injury model and alveolar macrophage responses. These data further support the idea that the functional roles of C/EBPb and C/EBPd in inflammation are cell and tissue specific.
In summary, we present evidence that mutant mice defective in C/EBPb were significantly protected from acute lung inflammation and injury following intrapulmonary deposition of IgG immune complexes. Our study indicates that understanding the underlying roles of various transcriptional factors in regulating the pulmonary inflammation may be a crucial step for devising new therapeutic strategies for treatment of acute lung injury.
